Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Apr 20;31(12):1522-9.
doi: 10.1200/JCO.2012.45.4181. Epub 2013 Mar 18.

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Randomized Controlled Trial

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Boris Böll et al. J Clin Oncol. .


Purpose: Older patients with Hodgkin lymphoma (HL) account for approximately 20% of all HL patients. ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy is regarded as standard of care in these patients. However, little is known on feasibility and efficacy of ABVD in this age group.

Patients and methods: We analyzed the feasibility and efficacy of four cycles of ABVD in older patients age 60 to 75 years with early-stage HL who were treated within the German Hodgkin Study Group (GHSG) HD10 and HD11 trials; results were compared with those of younger patients treated within these trials.

Results: In total, 1,299 patients received four cycles of ABVD, and 117 of those patients were older than age 60 years (median, 65 years). In 14% of older patients, treatment was not administered according to protocol, mainly because of excessive toxicity. The mean delay of treatment was twice as high in the older patients (2.2 v 1.2 weeks). Fifty-nine percent of older patients achieved a relative dose-intensity of at least 80% compared with 85% of younger patients. Major toxicity (WHO grade 3 and 4), including leucopenia, nausea, infection, and others, was documented in 68% of older patients with a treatment-related mortality of 5%. Complete response was achieved in 89% of older patients, 3% had progressive disease, and 11% relapsed. At a median observation time of 92 months, 28% of the patients had died, and the 5-year progression-free survival estimate was 75% (95% CI, 66% to 82%).

Conclusion: In patients age ≥ 60 years with HL, four cycles of ABVD is associated with substantial dose reduction, treatment delay, toxicity, and treatment-related mortality.

Trial registration: NCT00264953 NCT00265018.

Comment in

Similar articles

See all similar articles

Cited by 11 articles

  • Current Treatment Options for Older Patients with Hodgkin Lymphoma.
    Carter J, David KA, Kritharis A, Evens AM. Carter J, et al. Curr Treat Options Oncol. 2020 Apr 23;21(5):42. doi: 10.1007/s11864-020-00745-9. Curr Treat Options Oncol. 2020. PMID: 32328822 Review.
  • Management of older Hodgkin lymphoma patients.
    Evens AM, Carter J, Loh KP, David KA. Evens AM, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):233-242. doi: 10.1182/hematology.2019000028. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808898
  • Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
    Ramchandren R, Domingo-Domènech E, Rueda A, Trněný M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM. Ramchandren R, et al. J Clin Oncol. 2019 Aug 10;37(23):1997-2007. doi: 10.1200/JCO.19.00315. Epub 2019 May 21. J Clin Oncol. 2019. PMID: 31112476 Clinical Trial.
  • Moving things forward in Hodgkin lymphoma.
    Bröckelmann PJ, Böll B. Bröckelmann PJ, et al. F1000Res. 2018 Nov 13;7:F1000 Faculty Rev-1786. doi: 10.12688/f1000research.16077.1. eCollection 2018. F1000Res. 2018. PMID: 30473768 Free PMC article. Review.
  • Management of Lymphomas: Consensus Document 2018 by an Indian Expert Group.
    Nair R, Kakroo A, Bapna A, Gogia A, Vora A, Pathak A, Korula A, Chakrapani A, Doval D, Prakash G, Biswas G, Menon H, Bhattacharya M, Chandy M, Parihar M, Vamshi Krishna M, Arora N, Gadhyalpatil N, Malhotra P, Narayanan P, Nair R, Basu R, Shah S, Bhave S, Bondarde S, Bhartiya S, Nityanand S, Gujral S, Tilak TVS, Radhakrishnan V. Nair R, et al. Indian J Hematol Blood Transfus. 2018 Jul;34(3):398-421. doi: 10.1007/s12288-018-0991-4. Epub 2018 Aug 3. Indian J Hematol Blood Transfus. 2018. PMID: 30127547 Free PMC article. Review.
See all "Cited by" articles

Publication types

MeSH terms

Supplementary concepts

Associated data